{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:09:38Z","timestamp":1766066978142,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009996","name":"Sigma-Tau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009996","name":"Sigma-Tau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clbc.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T02:19:12Z","timestamp":1555553952000},"page":"311-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Maciej M.","family":"Mrugala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda F.","family":"Kurland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Gralow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2019.04.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nec.2010.08.007","article-title":"Epidemiology of metastatic brain tumors","volume":"22","author":"Fox","year":"2011","journal-title":"Neurosurg Clin N Am"},{"issue":"Suppl 4","key":"10.1016\/j.clbc.2019.04.004_bib2","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.4103\/2152-7806.111296","article-title":"Epidemiology and prognosis of brain metastases","volume":"4","author":"Stelzer","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.clbc.2019.04.004_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2014.25","article-title":"Current approaches to the treatment of metastatic brain tumours","volume":"11","author":"Owonikoko","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2007.09.059","article-title":"Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis","volume":"71","author":"Li","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2019.04.004_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2010.07.013","article-title":"Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)","volume":"72","author":"Galetta","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3816\/CLC.2010.n.022","article-title":"Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study","volume":"11","author":"Chua","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijrobp.2004.04.061","article-title":"Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial","volume":"61","author":"Verger","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2019.04.004_bib9","first-page":"361","article-title":"Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors","volume":"30","author":"Kouvaris","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.clbc.2019.04.004_bib10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/cncr.22127","article-title":"Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma","volume":"107","author":"Rivera","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2019.04.004_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","article-title":"The biology of brain metastases-translation to new therapies","volume":"8","author":"Eichler","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4155\/tde.15.48","article-title":"Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer","volume":"6","author":"Papademetriou","year":"2015","journal-title":"Ther Deliv"},{"key":"10.1016\/j.clbc.2019.04.004_bib14","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2019.04.004_bib15","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W","article-title":"Chemotherapy induces regression of brain metastases in breast carcinoma","volume":"58","author":"Rosner","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","article-title":"Systemic high-dose intravenous methotrexate for central nervous system metastases","volume":"78","author":"Lassman","year":"2006","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2019.04.004_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/07357909009012049","article-title":"Combination therapy with platinum and etoposide of brain metastases from breast carcinoma","volume":"8","author":"Cocconi","year":"1990","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clbc.2019.04.004_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/annonc\/mdu488","article-title":"Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer","volume":"26","author":"Cao","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1012226718323","article-title":"A\u00a0phase II trial of temozolomide for patients with recurrent or progressive brain metastases","volume":"53","author":"Abrey","year":"2001","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib22","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/cncr.23859","article-title":"Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases","volume":"113","author":"Addeo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","article-title":"Capecitabine therapy of central nervous system metastases from breast cancer","volume":"85","author":"Ekenel","year":"2007","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00043426-198921000-00017","article-title":"Central nervous system pharmacology of antileukemic drugs","volume":"11","author":"Balis","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1983.1.9.546","article-title":"Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid","volume":"1","author":"Slevin","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib27","first-page":"6101","article-title":"Pharmacokinetics of intraventricular and intravenous N,N',N''-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans","volume":"46","author":"Strong","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2019.04.004_bib28","first-page":"3394","article-title":"A\u00a0randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"18 Suppl","key":"10.1016\/j.clbc.2019.04.004_bib29","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1200\/jco.2006.24.18_suppl.1528","article-title":"A\u00a0randomized phase III\/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis","volume":"24","author":"Shapiro","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1054\/bjoc.2000.1574","article-title":"Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine","volume":"84","author":"Jaeckle","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib31","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1","article-title":"Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy","volume":"82","author":"Bokstein","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2019.04.004_bib32","first-page":"694","article-title":"Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases","volume":"87","author":"Chamberlain","year":"1997","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.clbc.2019.04.004_bib33","first-page":"216","article-title":"Ommaya reservoir-related infections: clinical manifestations and treatment outcomes","volume":"68","author":"Szvalb","year":"2014","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.clbc.2019.04.004_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11060-012-0880-x","article-title":"Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series","volume":"109","author":"Chamberlain","year":"2012","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2019.04.004_bib35","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","article-title":"Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919300990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919300990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:19Z","timestamp":1761513559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820919300990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1526820919300990"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2019.04.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}